Neutralase

Neutralase

Heparinase I Cardiology An agent used after cardiac bypass surgery to reverse heparin's anticoagulant effects. See Heparin.
References in periodicals archive ?
On September 22, 2003, BioMarin announced that it halted the Phase 3a trial of Neutralase in coronary artery bypass graft surgery and discontinued the Neutralase drug development program.
including the following potential future products: Aldurazyme for the treatment of MPS I, Neutralase for the reversal of anticoagulants, Aryplase for the treatment of MPS VI, and NeuroTrans for the delivery of enzymes across the blood-brain barrier.
announced that it halted its Phase 3a study of Neutralase(TM) for the reversal of anticoagulation by heparin in primary Coronary Artery Bypass Graft (CABG) surgery and that it has terminated its Neutralase program for all indications.
Neutralase is an injectable heparinase that is targeted to reverse heparin and other new heparin-like anticoagulants during open heart and other surgeries.
Other Recent Clinical and Development Milestones * BioMarin has obtained Institutional Review Board approval at multiple sites, and expects patient enrollment in February 2003 for its Phase 3 clinical trial of Neutralase for reversal of heparin in Coronary Artery Bypass Graft (CABG) Surgery, including both 'on pump' and 'off pump' procedures.
On September 30, 2002, BioMarin announced that it completed critical steps to begin patient enrollment for its Phase 3 trial of Neutralase for reversal of heparin in Coronary Artery Bypass Graft (CABG) surgery.
In October 2001, we acquired the Neutralase (TM) and Phenylase product programs from IBEX Technologies, Inc.
BioMarin expects to initiate a Phase III clinical trial of Neutralase for use in coronary artery bypass graft (CABG) surgery in 2002.
BioMarin intends to use the net proceeds from its sale of shares for the development and commercialization of its lead product candidate, Aldurazyme (TM) (used in the treatment of MPS I), for additional clinical trials and manufacturing of Neutralase (TM) (used in the reversal of heparin anticoagulation), for preclinical studies and clinical trials for its other product candidates, for potential licenses and other acquisitions of complementary technologies and products, for general corporate purposes, and for working capital.
Neutralase is an injectable heparinase that reverses the anticoagulation of blood by heparin and other new heparin-like anticoagulants.
BioMarin intends to use the net proceeds from its sale of shares to fund development and commercialization of its lead product candidate, Aldurazyme (TM) for the treatment of MPS I; additional clinical trials and manufacturing of Neutralase (TM) for the reversal of heparin anticoagulation; preclinical studies and clinical trials for its other product candidates; potential licenses and other acquisitions of complementary technologies and products; general corporate purposes; and working capital.
Neutralase is a carbohydrate-modifying enzyme that cleaves heparin, a glycosaminoglycan (GAG), in a manner similar to the activity of BioMarin's two enzyme replacement therapies: Aldurazyme(TM) for the treatment of MPS I and rhASB for the treatment of MPS VI.